Sign In
Search Icon
Menu Icon

Project NextGen

Enhancing Preparedness for Future COVID-19 Strains  & Variants 
with Next Generation Medical Countermeasures

The U.S. is in a better place in our response than at any point of the COVID-19 pandemic. However, we need to continue to support the development of a new generation of tools to stay ahead of COVID-19.

With an initial investment of $5 billion, Project NextGen will accelerate and streamline the rapid development of the next generation of vaccines and treatments through public-private collaborations.

Led by ASPR’s BARDA and National Institutes of Health’s NIAID, Project NextGen will coordinate across the federal government and the private sector to advance the pipeline of new, innovative vaccines and therapeutics from labs to clinical trials to potential FDA authorization, approval, and commercial availability for people nationwide.

Areas of Focus

nasal spray icon

Vaccines that are Easier to Administer and Reduce Spread of the Virus

Mucosal vaccines such as those delivered intranasally, which could have the potential to dramatically reduce infection and transmission, in addition to preventing serious illness and death.

clock icon

Better Protection.
Longer Lasting

Vaccines that provide broader protection against variants of concern and a longer duration of protection.

Coronaviruses icon

Innovative Solutions for Faster, Cheaper, Rapidly Deployable Technologies

Advancing new technologies that will improve access and enable faster, lower cost, rapid, and flexible production of vaccines and therapeutics.


Coronaviruses icon

Pan-Corona Virus

Pan-Corona virus vaccines which protects against several different coronaviruses.

clock icon

Modernized, More Resilient Treatments

New and more durable monoclonal antibodies that are resilient against new variants as they arise.

To learn more about Project NextGen, check out the HHS Fact Sheet: Fact Sheet: HHS Announces $5 Billion ‘Project NextGen’ Initiative to Stay Ahead of COVID-19.

Read the Fact Sheet

Program Areas of Advanced Research and Development

Strenthen. COVID-19 Vacciness. Povide broader, more durable protection. Better transmission block capabilities.  
Treat. COVID-19 Therapeutics. Enhanced monoclonal antibody therapeutics. Pre-exposure prophylaxis monoclonal antibodies.  
Enable Advanced Technology. Technology at lower cost. Accelerate production. Increase access to critical medical countermeasures  

Open Collaboration and Funding Opportunities

Request a TechWatch Meeting

Prior to submitting to the Broad Agency Announcement (BAA), BARDA encourages you to request a TechWatch meeting. A TechWatch meeting provides prospective partners with the opportunity to receive feedback about the potential product or technology from BARDA staff. 

Submission of a TechWatch meeting request does not guarantee a meeting or funding.

Request a Meeting

Project NextGen Overview with Robert Johnson